Tags : Manufacturing

AstraZeneca Signs an Agreement with Emergent BioSolutions to Expand Manufacturing

Shots: Emergent will provide CDMO services for AstraZeneca’ AZD1222. The agreement valued ~174M through 2021 and follows an $87M agreement signed in June for development services, performance and process qualification, raw materials, and an initial capacity reservation The two companies may enter additional commercial manufacturing agreement as the candidate progresses over three years through Emergent’s […]Read More

Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia

Shots: The two companies expand their 2018 agreement to develop and manufacture five candidates from ImmuneOncia’s pipeline. The partners expand the collaboration to bring new treatments such as IMC-002 for cancer patients Samsung Biologics to provide CDO services from cell line development, process development, non-clinical/clinical material manufacturing, to IND submission supporting the global clinical trials […]Read More

Emergent Signs a Five-Year Manufacturing Services Agreement with Janssen for

Shots: Emergent will be responsible to provide large-scale drug substance for manufacturing Janssen’s Ad26.COV2-S for the first two years valued at ~$480M in 2021. Additionally, at the beginning of 2023 Emergent will provide capacity deployment model for supporting additional drug substance batches annually for three years The manufacturing practices will be performed at Emergent’s Baltimore […]Read More

GSK Collaborates with Samsung Biologics for Large Scale Biopharmaceutical Manufacturing

Shots: The companies collaborated to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies. The eight-year contract is valued at more than $231M This capacity will be flexible depending on GSK’s future needs and will supplement GSK’s existing manufacturing network Samsung Biologics will commercially produce GSK’s Benlysta (belimumab) with technology transfer […]Read More

Janssen Collaborates with Emergent BioSolutions to Accelerate the Manufacturing of

Shots: Janssen partnered with Emergent to develop more than a billion doses of a COVID-19 vaccine candidate, as it anticipates scaling up global manufacturing of its potential treatment. The agreement valued ~135M Emergent will provide manufacturing services with its molecule-to-market CDMO offering, beginning in 2020 and will reserve operations capacity to support manufacturing of J&J’s […]Read More

Just – Evotec Signs a Development and Manufacturing Agreement with

Shots: Just-Evotec to leverage its technology platform, J.Design to accelerate OncoResponse’s OR2805 through the development and into the clinic Just-Evotec provides services to the OncoResponse which includes cell line development, process development, and P-I/II cGMP clinical manufacturing of OR2805 in human clinical studies OncoResponse’s OR2805 is an Ab, reversing the immunosuppression in the tumor microenvironment […]Read More

Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application

Shots: Sun Pharma has filed manufacturing and marketing authorization of Tildrakizumab to the PMDA for moderate-to-severe psoriasis and psoriatic arthritis in Japan Additionally, Sun Pharma has acquired Pola Pharma and will leverage Pola’s strong presence in the dermatology to commercialize Tildrakizumab in Japan which will expand Sun Pharma’s global franchise and robust its dermatology pipeline […]Read More

Sangamo Therapeutics Signs an Option Agreement with Brammer Bio for

Shots: Sangamo has an option to access Brammer’s AAV manufacturing facility with 2000-L bioreactor scale used in development of gene therapies. Additionally, Sangamo has rights for Brammer’s viral vector manufacturing facility to utilize it in combination with its California facility to expand its early stage products to late stage The focus of the agreement is […]Read More